206 related articles for article (PubMed ID: 34293141)
1. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Carrat F; de Lamballerie X; Rahib D; Blanché H; Lapidus N; Artaud F; Kab S; Renuy A; Szabo de Edelenyi F; Meyer L; Lydié N; Charles MA; Ancel PY; Jusot F; Rouquette A; Priet S; Saba Villarroel PM; Fourié T; Lusivika-Nzinga C; Nicol J; Legot S; Druesne-Pecollo N; Esseddik Y; Lai C; Gagliolo JM; Deleuze JF; Bajos N; Severi G; Touvier M; Zins M;
Int J Epidemiol; 2021 Nov; 50(5):1458-1472. PubMed ID: 34293141
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.
Lachassinne E; de Pontual L; Caseris M; Lorrot M; Guilluy C; Naud A; Dommergues MA; Pinquier D; Wannepain E; Hausherr E; Jung C; Gajdos V; Cohen R; Zahar JR; Brichler S; Basmaci R; Boelle PY; Bloch-Queyrat C; Aupiais C;
Lancet Child Adolesc Health; 2021 Apr; 5(4):256-264. PubMed ID: 33571450
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
5. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
6. Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort.
Warszawski J; Beaumont AL; Seng R; de Lamballerie X; Rahib D; Lydié N; Slama R; Durrleman S; Raynaud P; Sillard P; Beck F; Meyer L; Bajos N;
BMC Infect Dis; 2022 Jan; 22(1):41. PubMed ID: 35000580
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study.
Carrat F; Touvier M; Severi G; Meyer L; Jusot F; Lapidus N; Rahib D; Lydié N; Charles MA; Ancel PY; Rouquette A; de Lamballerie X; Zins M; Bajos N;
BMC Infect Dis; 2021 Feb; 21(1):169. PubMed ID: 33568097
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
Murhekar MV; Bhatnagar T; Selvaraju S; Rade K; Saravanakumar V; Vivian Thangaraj JW; Kumar MS; Shah N; Sabarinathan R; Turuk A; Anand PK; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Rangaraju C; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Salim Khan SM; Haq I; Kumar MS; Laxmaiah A; Madhuka ; Mahapatra A; Mitra A; Nirmala AR; Pagdhune A; Qurieshi MA; Ramarao T; Sahay S; Sharma YK; Shrinivasa MB; Shukla VK; Singh PK; Viramgami A; Wilson VC; Yadav R; Girish Kumar CP; Luke HE; Ranganathan UD; Babu S; Sekar K; Yadav PD; Sapkal GN; Das A; Das P; Dutta S; Hemalatha R; Kumar A; Narain K; Narasimhaiah S; Panda S; Pati S; Patil S; Sarkar K; Singh S; Kant R; Tripathy S; Toteja GS; Babu GR; Kant S; Muliyil JP; Pandey RM; Sarkar S; Singh SK; Zodpey S; Gangakhedkar RR; S Reddy DC; Bhargava B
Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):48-60. PubMed ID: 32952144
[TBL] [Abstract][Full Text] [Related]
11. Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.
Tang X; Sharma A; Pasic M; Brown P; Colwill K; Gelband H; Birnboim HC; Nagelkerke N; Bogoch II; Bansal A; Newcombe L; Slater J; Rodriguez PS; Huang G; Fu SH; Meh C; Wu DC; Kaul R; Langlois MA; Morawski E; Hollander A; Eliopoulos D; Aloi B; Lam T; Abe KT; Rathod B; Fazel-Zarandi M; Wang J; Iskilova M; Pasculescu A; Caldwell L; Barrios-Rodiles M; Mohammed-Ali Z; Vas N; Santhanam DR; Cho ER; Qu K; Jha S; Jha V; Suraweera W; Malhotra V; Mastali K; Wen R; Sinha S; Reid A; Gingras AC; Chakraborty P; Slutsky AS; Jha P;
JAMA Netw Open; 2022 Feb; 5(2):e2146798. PubMed ID: 35171263
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave.
Pouquet M; Decarreaux D; Di Domenico L; Sabbatini CE; Prévot-Monsacre P; Fourié T; Villarroel PMS; Priet S; Blanché H; Sebaoun JM; Deleuze JF; Turbelin C; Rossignol L; Werner A; Kochert F; Grosgogeat B; Rabiega P; Laupie J; Abraham N; Noël H; van der Werf S; Colizza V; Carrat F; Charrel R; de Lamballerie X; Blanchon T; Falchi A
Sci Rep; 2024 Mar; 14(1):5418. PubMed ID: 38443618
[TBL] [Abstract][Full Text] [Related]
13. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study.
Snyder T; Ravenhurst J; Cramer EY; Reich NG; Balzer L; Alfandari D; Lover AA
BMJ Open; 2021 Aug; 11(8):e051157. PubMed ID: 34404716
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
[TBL] [Abstract][Full Text] [Related]
15. Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort-EPICOV.
Warszawski J; Meyer L; Franck JE; Rahib D; Lydié N; Gosselin A; Counil E; Kreling R; Novelli S; Slama R; Raynaud P; Bagein G; Costemalle V; Sillard P; Fourie T; de Lamballerie X; Bajos N;
PLoS One; 2022; 17(5):e0267725. PubMed ID: 35613100
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
[TBL] [Abstract][Full Text] [Related]
18. Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.
Racey CS; Booth A; Albert A; Smith LW; Krajden M; Murray MCM; Côté HCF; Gottschlich A; Goldfarb DM; Sadarangani M; Galea LAM; Kaida A; Brotto LA; Ogilvie GS
BMJ Open; 2022 Aug; 12(8):e062567. PubMed ID: 36038173
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark.
Fogh K; Eriksen ARR; Hasselbalch RB; Kristensen ES; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Norsk J; Nielsen PB; Kristensen JH; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause TG; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
BMC Infect Dis; 2022 Feb; 22(1):143. PubMed ID: 35144550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
